<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00894179</url>
  </required_header>
  <id_info>
    <org_study_id>REGA-9B04</org_study_id>
    <nct_id>NCT00894179</nct_id>
  </id_info>
  <brief_title>Safety and Accuracy Study of Regadenoson Atropine Combination for Stress Echocardiography in Identification of Coronary Artery Disease</brief_title>
  <acronym>REGAT</acronym>
  <official_title>Feasibility, Safety and Accuracy of Regadenoson-Atropine ( REGAT) Stress Echocardiography for the Diagnosis of Coronary Artery Disease: An Angiographic Correlative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The investigators plan to test a newly FDA approved pharmacologic stress agent,&#xD;
      Regadenoson, in conjunction with atropine in the use of stress echocardiography for the&#xD;
      diagnosis of coronary artery disease. The selective nature of Regadenoson allows for its use&#xD;
      in patients with contraindications to the currently used drug, Adenosine, which is&#xD;
      non-selective. Furthermore, the proposed protocol can be completed faster and without&#xD;
      radiation exposure than the current protocol with adenosine.&#xD;
&#xD;
      Design: This is a prospective study evaluating people with no prior diagnosis of coronary&#xD;
      disease with a prior stress test and are scheduled for cardiac catheterization. Patients who&#xD;
      meet inclusion criteria will undergo regadenoson-atropine echocardiography protocol prior to&#xD;
      their catheterization. The study will be interpreted by two independent readers blinded to&#xD;
      the catheterization results. The sensitivity, specificity, positive and negative predictive&#xD;
      values of the regadenoson-atropine study will be then be calculated using the coronary&#xD;
      angiogram as a gold standard.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the sensitivity, specificity, positive and negative predictive value and accuracy of REGAT stress echocardiography protocol in the detection of coronary artery disease, using &gt; 70% luminal stenosis on coronary angiogram as gold standard.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability (using patient questionnaire) of REGAT stress echocardiography</measure>
    <time_frame>1-7 days after stress test</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare sensitivity, specificity, positive and negative predicative value and accuracy of a REGAT stress echocardiography protocol to other stress imaging modalities used in the patient cohort as per design of study</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This will be a prospective study evaluating stable outpatients with no prior diagnosis of&#xD;
        coronary disease who may or may not have had a prior functional stress imaging test and are&#xD;
        going for a clinically indicated cardiac catheterization as deemed by their physician due&#xD;
        to suspected coronary artery disease either based on symptoms or based on results for prior&#xD;
        functional testing&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years old&#xD;
&#xD;
          2. Able to provide consent&#xD;
&#xD;
          3. Scheduled for cardiac catheterization either with or without a prior functional stress&#xD;
             imaging study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any history of acute myocardial infarction, prior PCI in last 3 months, bypass&#xD;
             surgery,&#xD;
&#xD;
          2. History of greater than first degree AV block, sick sinus syndrome in patients&#xD;
&#xD;
          3. Patients with a pacemaker/LBBB&#xD;
&#xD;
          4. History on uncontrolled arrhythmias&#xD;
&#xD;
          5. Patients with significant pulmonary disease, known or suspected bronchoconstrictive or&#xD;
             bronchospastic lung disease or other hypersensitivity to adenosine&#xD;
&#xD;
          6. History of cardiac transplantation, hypertrophic cardiomyopathy, acute myocarditis or&#xD;
             pericarditis, severe valvular heart disease&#xD;
&#xD;
          7. Hemodynamically unstable patients&#xD;
&#xD;
          8. Dipyridamole use within 30 hours, consumption of methylxanthines (e.g., tea, coffee,&#xD;
             caffeinated soft drinks, chocolate, or cocoa) within 12 hours, or use of sublingual&#xD;
             nitroglycerin within 2 hours&#xD;
&#xD;
          9. History of glaucoma or obstructive uropathy&#xD;
&#xD;
         10. Allergy or hypersensitivity to atropine&#xD;
&#xD;
         11. Participation in another investigational drug study within 1 month or participation in&#xD;
             any previous regadenoson trial&#xD;
&#xD;
         12. Pregnancy, breast feeding, or not using an acceptable method of birth control (if&#xD;
             premenopausal)&#xD;
&#xD;
         13. . History of end-stage renal disease on hemodialysis or peritoneal dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karthikeyan Ananthasubramaniam, MD FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karthikeyan Ananthasubramaniam, MD FACC</last_name>
    <phone>313-916-2721</phone>
    <email>kananth1@hfhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dee Dee Wang, MD</last_name>
    <phone>313-916-2721</phone>
    <email>DWANG2@hfhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karthikeyan Ananthasubramaniam, MD</last_name>
      <phone>313-916-2721</phone>
      <email>kananth1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Dee Dee Wang, MD</last_name>
      <phone>313-916-2721</phone>
      <email>DWANG2@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Karthikeyan Ananthasubramaniam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Karthikeyan Ananthasubramaniam</name_title>
    <organization>Henry Ford Hospital</organization>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>stress echocardiography</keyword>
  <keyword>regadenoson</keyword>
  <keyword>atropine</keyword>
  <keyword>coronary angiogram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>July 16, 2013</submitted>
    <returned>September 20, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

